Chinese Journal of Dermatology ›› 2022, e20210442.doi: 10.35541/cjd.20210442
• Reviews • Previous Articles Next Articles
Sui Changlin, Chang Xiao, Zhao Qi, Zhu Wei
Received:
2021-06-10
Revised:
2022-03-18
Online:
2022-01-01
Published:
2022-05-06
Contact:
Zhu Wei
E-mail:zhuwei@xwh.ccmu.edu.cn
Sui Changlin, Chang Xiao, Zhao Qi, Zhu Wei. Psoriasis induced by anti-tumor targeted therapy and immunotherapy[J]. Chinese Journal of Dermatology,2022,e20210442. doi:10.35541/cjd.20210442
[1] | Zaki SA. Adverse drug reaction and causality assessment scales[J]. Lung India, 2011,28(2):152⁃153. doi: 10.4103/0970⁃2113. 80343. |
[2] | George A, George R. Nivolumab (PD⁃1 inhibitor) induced exacerbation of psoriasis[J]. Indian Dermatol Online J, 2020,11(2):261⁃262. doi: 10.4103/idoj.IDOJ_47_19. |
[3] | Yamamoto T. Anti⁃programmed cell death⁃1⁃induced plaque and guttate psoriasis[J]. Indian J Dermatol, 2018, 63(1):88⁃89. doi: 10.4103/ijd.IJD_46_17. |
[4] | Mayor Ibarguren A, Enrique EA, Diana PL, et al. Apremilast for immune checkpoint inhibitor⁃induced psoriasis: a case series[J]. JAAD Case Rep, 2021,11:84⁃89. doi: 10.1016/j.jdcr.2021.03.015. |
[5] | Politi A, Angelos D, Mauri D, et al. A case report of psoriasis flare following immunotherapy: report of an important entity and literature review[J]. SAGE Open Med Case Rep, 2020,8:2050313X19897707. doi: 10.1177/2050313X19897707. |
[6] | Mullangi S, Ponnam S, Lekkala MR, et al. A case of de novo psoriasis secondary to nivolumab in a patient with metastatic renal cell carcinoma[J]. Cureus, 2021,13(6):e15703. doi: 10.7759/cureus.15703. |
[7] | Glinos GD, Fisher WS, Morr CS, et al. Nivolumab⁃induced psoriasis successfully treated with risankizumab⁃rzaa in a patient with stage III melanoma[J]. JAAD Case Rep, 2021,11:74⁃77. doi: 10.1016/j.jdcr.2021.03.029. |
[8] | Marti⁃Marti I, Gómez S, Riera⁃Monroig J, et al. Rupioid psoriasis induced by pembrolizumab[J]. Indian J Dermatol Venereol Leprol, 2020,86(5):580⁃582. doi: 10.4103/ijdvl.IJDVL_1067_19. |
[9] | Scarfì F, Lacava R, Patrizi A, et al. Follicular psoriasis induced by pembrolizumab in a patient with advanced non⁃small⁃cell lung cancer[J]. Int J Dermatol, 2019,58(8):e151⁃e152. doi: 10.1111/ijd.14457. |
[10] | Siciliano MA, Dastoli S, d′Apolito M, et al. Pembrolizumab⁃induced psoriasis in metastatic melanoma: activity and safety of apremilast, a case report[J]. Front Oncol, 2020,10:579445. doi: 10.3389/fonc.2020.579445. |
[11] | Takama H, Shibata T, Ando Y, et al. Pembrolizumab⁃induced psoriasis vulgaris successfully treated with apremilast[J]. Eur J Dermatol, 2020,30(2):188⁃190. doi: 10.1684/ejd.2020.3723. |
[12] | Monsour EP, Pothen J, Balaraman R. A novel approach to the treatment of pembrolizumab⁃induced psoriasis exacerbation: a case report[J]. Cureus, 2019,11(10):e5824. doi: 10.7759/cureus.5824. |
[13] | Huang PW, Chu CY. Pembrolizumab⁃induced linear psoriasis[J]. Lung Cancer, 2020,146:378⁃379. doi: 10.1016/j.lungcan. 2020.06.012. |
[14] | Sahuquillo⁃Torralba A, Ballester⁃Sánchez R, Pujol⁃Marco C, et al. Pembrolizumab: a new drug that can induce exacerbations of psoriasis[J]. Actas Dermosifiliogr, 2016,107(3):264⁃266. doi: 10.1016/j.ad.2015.07.012. |
[15] | Sui CL, Lin XF, He L, et al. Dermoscopic features of acutely exacerbated plaque psoriasis induced by anti⁃programmed death⁃1 for lung cancer[J]. Chin Med J (Engl), 2020,133(17):2123⁃2125. doi: 10.1097/CM9.0000000000000958. |
[16] | De Bock M, Hulstaert E, Kruse V, et al. Psoriasis vulgaris exacerbation during treatment with a PD⁃1 checkpoint inhibitor: case report and literature review[J]. Case Rep Dermatol, 2018,10(2):190⁃197. doi: 10.1159/000491572. |
[17] | Nonomura Y, Otsuka A, Ohtsuka M, et al. ADAMTSL5 is upregulated in melanoma tissues in patients with idiopathic psoriasis vulgaris induced by nivolumab[J]. J Eur Acad Dermatol Venereol, 2017,31(2):e100⁃e101. doi: 10.1111/jdv. 13818. |
[18] | Tanaka R, Ichimura Y, Kubota N, et al. Activation of CD8 T cells accelerates anti⁃PD⁃1 antibody⁃induced psoriasis⁃like dermatitis through IL⁃6[J]. Commun Biol, 2020,3(1):571. doi: 10.1038/s42003⁃020⁃01308⁃2. |
[19] | Bonigen J, Raynaud⁃Donzel C, Hureaux J, et al. Anti⁃PD1⁃induced psoriasis: a study of 21 patients[J]. J Eur Acad Dermatol Venereol, 2017,31(5):e254⁃e257. doi: 10.1111/jdv. 14011. |
[20] | Sibaud V. Dermatologic reactions to immune checkpoint inhibitors : skin toxicities and immunotherapy[J]. Am J Clin Dermatol, 2018,19(3):345⁃361. doi: 10.1007/s40257⁃017⁃0336⁃3. |
[21] | Halle BR, Betof Warner A, Zaman FY, et al. Immune checkpoint inhibitors in patients with pre⁃existing psoriasis: safety and efficacy[J]. J Immunother Cancer, 2021,9(10):e003066. doi: 10.1136/jitc⁃2021⁃003066. |
[22] | Marinello E, Pastorelli D, Alaibac M. A case of psoriasis pustolosa palmaris induced by cetuximab[J]. BMJ Case Rep, 2016,2016:bcr2016214582. doi: 10.1136/bcr⁃2016⁃214582. |
[23] | Kamaria M, Shea CR, Chin RK, et al. Eruptive cutaneous squamous cell carcinoma and psoriasis: response to cetuximab[J]. Clin Exp Dermatol, 2014,39(5):604⁃607. doi: 10.1111/ced.12341. |
[24] | Abe S, Ueno M, Nishitani M, et al. Citrus sudachi peel extract suppresses cell proliferation and promotes the differentiation of keratinocytes through inhibition of the EGFR⁃ERK signaling pathway[J]. Biomolecules, 2020,10(10):1468. doi: 10.3390/biom10101468. |
[25] | Le A, Azouz A, Thomas S, et al. JNK1 signaling downstream of the EGFR pathway contributes to aldara®⁃induced skin inflammation[J]. Front Immunol, 2020,11:604785. doi: 10.3389/fimmu.2020.604785. |
[26] | Furue K, Ito T, Tanaka Y, et al. The EGFR⁃ERK/JNK⁃CCL20 pathway in scratched keratinocytes may underpin koebnerization in psoriasis patients[J]. Int J Mol Sci, 2020,21(2):434. doi: 10.3390/ijms21020434. |
[27] | de Lorenzi C, Kaya G, Quenan S. Psoriasis induced by trastuzumab therapy[J]. Eur J Dermatol, 2018,28(5):702⁃704. doi: 10.1684/ejd.2018.3395. |
[28] | Kim DW, Park SK, Woo SH, et al. New⁃onset psoriasis induced by rituximab therapy for non⁃Hodgkin lymphoma in a child[J]. Eur J Dermatol, 2016,26(2):190⁃191. doi: 10.1684/ejd.2015. 2705. |
[29] | Haller C, Cozzio A, von Kempis J, et al. Successful treatment of rituximab⁃associated palmoplantar pustulosis with apremilast in a patient with seropositive rheumatoid arthritis[J]. J Clin Rheumatol, 2021,27(7):e289⁃e290. doi: 10.1097/RHU.000000 0000001415. |
[30] | Koumaki D, Koumaki V, Haniotis V, et al. Erythrodermic psoriasis after rituximab treatment in a patient with autoimmune hemolytic anemia[J]. Indian J Dermatol, 2021,66(1):108⁃112. doi: 10.4103/ijd.IJD_336_19. |
[31] | Fiorillo L, Wang C, Hemmati I. Rituximab induced psoriasis in an infant[J]. Pediatr Dermatol, 2014,31(6):e149⁃e151. doi: 10. 1111/pde.12437. |
[32] | Guidelli GM, Fioravanti A, Rubegni P, et al. Induced psoriasis after rituximab therapy for rheumatoid arthritis: a case report and review of the literature[J]. Rheumatol Int, 2013,33(11):2927⁃2930. doi: 10.1007/s00296⁃012⁃2581⁃3. |
[33] | Chang YS, Lee HT, Chen WS, et al. Treatment of psoriasis with rituximab[J]. J Am Acad Dermatol, 2012,66(5):e184⁃e185. doi: 10.1016/j.jaad.2010.08.007. |
[34] | Şimşek T, Yıldırım N, Efe B, et al. Rituximab treatment in a patient with active Graves′ orbitopathy and psoriasis[J]. Turk J Ophthalmol, 2017,47(1):42⁃46. doi: 10.4274/tjo.26780. |
[35] | Niu J, Zhai Z, Hao F, et al. Dissection of a circulating CD3+ CD20+ T cell subpopulation in patients with psoriasis[J]. Clin Exp Immunol, 2018,192(2):206⁃212. doi: 10.1111/cei. 13106. |
[36] | Alahmari HS, Alhowaish NY, Omair MA. Rituximab⁃induced psoriasis in a patient with granulomatosis with polyangitis treated with adalimumab[J]. Case Rep Rheumatol, 2019,2019:5450863. doi: 10.1155/2019/5450863. |
[37] | Machan S, Plaza C, Pérez⁃González Y, et al. Management of psoriasis⁃like rash associated with idelalisib monotherapy in a patient with refractory follicular lymphoma: a case report[J]. J Med Case Rep, 2020,14(1):35. doi: 10.1186/s13256⁃020⁃2344⁃9. |
[38] | Pesqué D, Sanchez⁃Gonzalez B, Gallardo F, et al. Psoriasiform eruption secondary to PI3K⁃delta inhibitor: expanding the spectrum of psoriasiform paradoxical reactions?[J]. Acta Derm Venereol, 2021,101(3):adv00418. doi: 10.2340/00015555⁃3783. |
[39] | Mercurio L, Morelli M, Scarponi C, et al. PI3Kδ sustains keratinocyte hyperproliferation and epithelial inflammation: implications for a topically druggable target in psoriasis[J]. Cells, 2021,10(10):2636. doi: 10.3390/cells10102636. |
[40] | Shim JH, Oh SH, Jun JY, et al. Exacerbation of psoriasis after imatinib mesylate treatment[J]. Ann Dermatol, 2016,28(3):409⁃411. doi: 10.5021/ad.2016.28.3.409. |
[41] | Thachil J. T⁃regulatory cell response in psoriasis and changes with imatinib therapy[J]. Clin Exp Dermatol, 2009,34(8):e1022. doi: 10.1111/j.1365⁃2230.2009.03696.x. |
[42] | Woo SM, Huh CH, Park KC, et al. Exacerbation of psoriasis in a chronic myelogenous leukemia patient treated with imatinib[J]. J Dermatol, 2007,34(10):724⁃726. doi: 10.1111/j.1346⁃8138. 2007.00369.x. |
[43] | Jain A. Imatinib Induced Complete Remission of psoriasis in a patient with chronic myeloid leukemia[J]. Indian J Hematol Blood Transfus, 2020,36(1):198⁃199. doi: 10.1007/s12288⁃019⁃01162⁃1. |
[44] | Kaur S, Arora AK, Sekhon JS, et al. Nilotinib⁃induced psoriasis in a patient of chronic myeloid leukemia responding to methotrexate[J]. Indian J Dermatol Venereol Leprol, 2015,81(2):216⁃218. doi: 10.4103/0378⁃6323.152311. |
[45] | Blake SJ, Lyons AB, Hughes TP. Nilotinib inhibits the Src⁃family kinase LCK and T⁃cell function in vitro[J]. J Cell Mol Med, 2009,13(3):599⁃601. doi: 10.1111/j.1582⁃4934.2009.00500_1.x. |
[46] | Fei F, Yu Y, Schmitt A, et al. Effects of nilotinib on regulatory T cells: the dose matters[J]. Mol Cancer, 2010,9:22. doi: 10.1186/1476⁃4598⁃9⁃22. |
[47] | Adachi T, Hiraoka A, Okazaki H, et al. Exacerbation of psoriasis vulgaris by sorafenib treatment for hepatocellular carcinoma[J]. Clin J Gastroenterol, 2020,13(5):891⁃895. doi: 10.1007/s12328⁃020⁃01134⁃3. |
[48] | Ohashi T, Yamamoto T. Exacerbation of psoriasis with pustulation by sorafenib in a patient with metastatic hepatocellular carcinoma[J]. Indian J Dermatol, 2019,64(1):75⁃77. doi: 10.4103/ijd.IJD_16_17. |
[49] | Zhao D, Zhai B, He C, et al. Upregulation of HIF⁃2α induced by sorafenib contributes to the resistance by activating the TGF⁃α/EGFR pathway in hepatocellular carcinoma cells[J]. Cell Signal, 2014,26(5):1030⁃1039. doi: 10.1016/j.cellsig.2014.01. 026. |
[50] | Rosenberger C, Solovan C, Rosenberger AD, et al. Upregulation of hypoxia⁃inducible factors in normal and psoriatic skin[J]. J Invest Dermatol, 2007,127(10):2445⁃2452. doi: 10.1038/sj.jid. 5700874. |
[51] | Tang W, Long T, Li F, et al. HIF⁃1α may promote glycolysis in psoriasis vulgaris via upregulation of CD147 and GLUT1[J]. J Cent South Univ (Med Sci), 2021,46(4):333⁃344. doi: 10.11817/ j.issn.1672⁃7347.2021.200010. |
[52] | van Kester MS, Luelmo S, Vermeer MH, et al. Remission of psoriasis during treatment with sorafenib[J]. JAAD Case Rep, 2018,4(10):1065⁃1067. doi: 10.1016/j.jdcr.2018.09.009. |
[53] | Sally R, Ugonabo N, Nguyen A, et al. Lenvatinib⁃induced psoriasiform eruption and palmoplantar erythema in a patient with hepatocellular carcinoma[J]. JAAD Case Rep, 2021,15:1⁃3. doi: 10.1016/j.jdcr.2021.07.001. |
[54] | Kimura T, Kato Y, Ozawa Y, et al. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1⁃6 hepatocellular carcinoma model[J]. Cancer Sci, 2018,109(12):3993⁃4002. doi: 10.1111/cas.13806. |
[1] | Chen Xingyu, Yao Xu. Role of neutrophils in inflammatory dermatoses [J]. Chinese Journal of Dermatology, 2024, 0(3): 20220865-e20220865. |
[2] | Wu Yubing, Wang Xiaoyu, An Binyi, Wu Yingying, Sang Hong, Kong Qingtao, . Role of cyclic guanosine monophosphate-adenosine monophosphate synthase-stimulator of interferon genes signaling pathway in the occurrence of psoriasis [J]. Chinese Journal of Dermatology, 2024, 0(3): 20230394-e20230394. |
[3] | Zhu Tingting, Zhang Xuejun. Apremilast in the treatment of plaque psoriasis [J]. Chinese Journal of Dermatology, 2024, 0(3): 20230448-e20230448. |
[4] | Hao Dan, Wang Yiyi, Xiao Yue, Yan Wei, Li Wei. Systemic treatment options for psoriasis in special areas [J]. Chinese Journal of Dermatology, 2024, 0(3): 20230190-e20230190. |
[5] | Zong Yangyongyi, Ma Chujun, Su Zhonglan. Eczematization following the treatment of psoriasis with biological agents: pathogenesis and management [J]. Chinese Journal of Dermatology, 2024, 0(3): 20220578-e20220578. |
[6] | Wang Yukun, Liu Jie. Application of deep learning in non-neoplastic dermatoses [J]. Chinese Journal of Dermatology, 2024, 0(3): 20220660-e20220660. |
[7] | Wang Shiqi, Wang Aiping, Li Hang, Li Ruoyu. Comparison of dermoscopic features of toenail psoriasis and fingernail psoriasis [J]. Chinese Journal of Dermatology, 2024, 57(2): 161-165. |
[8] | China Dermatologist Association, Chinese Society of Dermatology, Dermatology Branch of China International Exchange and Promotive Association for Medical and Health Care, State Key Laboratory of Complex Severe and Rare Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases. Expert consensus on the application and management of therapeutic drugs for atopic dermatitis (2024) [J]. Chinese Journal of Dermatology, 2024, 57(2): 97-108. |
[9] | Fu Dandan, Li Jialin, Fu Xiuyu, Zhang Xinyu, Hu Hua, Song Xiangfeng, Tian Zhongwei. S100A10 protein expression in psoriatic lesions and its effect on psoriasis-like skin inflammation in mouse models [J]. Chinese Journal of Dermatology, 2023, 56(9): 839-844. |
[10] | Liu Xiaoyang, Zhao Yan, Cai Lin, Zhang Jianzhong. Atopic dermatitis-like lesions appearing after interleukin-17 antagonist therapy in 4 cases of psoriasis: case analysis and literature review [J]. Chinese Journal of Dermatology, 2023, 56(9): 845-848. |
[11] | Song Zhiqiang, Chen Qiquan, Ge Lan. Insights into the progress in targeted therapy of atopic dermatitis from the perspective of its pathogenesis [J]. Chinese Journal of Dermatology, 2023, 56(8): 718-723. |
[12] | Chen Xiaomin, Zhang Jingzhan, Ding Yuan, Kang Xiaojing. Metformin in the treatment of psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(8): 799-802. |
[13] | Jiang Xiaoyan, Gao Min, Zhang Xiaoyan, Liu Ningyuan. Interleukin-17 and interleukin-23 inhibitors in the treatment of pustular psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(7): 689-692. |
[14] | Shan Ying, Chang Xiaotong, Zuo Yagang. Epitope spreading in autoimmune bullous diseases [J]. Chinese Journal of Dermatology, 2023, 56(7): 702-705. |
[15] | Tang Zhiming, Jing Mengqing, Lu Lu, Shan Xiao, Zhang Cuixia, Zhang Xiaoyu, Meng Sa. Effect of Xidi Liangxue recipe on the proliferation and apoptosis of HaCaT cells through the lncRNA NEAT1/miR-485-5p/STAT3 regulatory network [J]. Chinese Journal of Dermatology, 2023, 56(7): 642-650. |
|